This Tiny Biotech is the Investment of a Lifetime
Biotech's Next Big Giant?... ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ | | A Message from i2i Marketing Group, LLC Dear Reader, A few years from now... scars may be a thing of the past. Just imagine...children of future generations may never even know what a scar is. It could be completely foreign to them. Like smallpox. And polio. That's how profound this tiny biotech's treatment could be. But this goes far beyond just scars. Up to 45% of the deaths in the world from fibrosis could potentially be prevented... Type 1 diabetes could be cured and wiped off the planet. Alopecia and other autoimmune disorders... gone for good. In what could be just weeks from now, this tiny company is poised to go public on the NASDAQ. And it won't be long before this treatment could be found in every hospital and doctor's office around the country. Right now you have a chance to get in before the public... If you want to take advantage of this limited window… it may still be open. Best,
Editor |
|
|
|
|
Thank you for subscribing to DividendStocks.com's daily newsletter for dividend and income investors that covers ex-dividend stocks, new dividend declarations, dividend stock ideas, and the latest market news.
This message is a paid advertisement sent on behalf of i2i Marketing Group, LLC, a third-party advertiser of DividendStocks.com and MarketBeat.
This message is a paid advertisement for BirchBioMed from i2i Marketing Group, LLC and Summit Publishing. MarketBeat Media, LLC receives a fixed fee for each subscriber that clicks on a link in this email, totaling up to $4,500. Other than the compensation received for this advertisement sent to subscribers, MarketBeat and its principals are not affiliated with either i2i Marketing Group, LLC or Summit Publishing. MarketBeat and its principals do not own any of the stocks mentioned in this email or in the article that this email links to. Neither MarketBeat nor its principals are FINRA-registered broker-dealers or investment advisers. The content of this email should not be taken as advice, an endorsement, or a recommendation from MarketBeat to buy or sell any security. MarketBeat has not evaluated the accuracy of any claims made in this advertisement. MarketBeat recommends that investors do their own independent research and consult with a qualified investment professional before buying or selling any security. Investing is inherently risky. Past-performance is not indicative of future results. Please see the disclaimer regarding BirchBioMed on Summit Publishing' website for additional information about the relationship between Summit Publishing and BirchBioMed.
If you have questions about your subscription, feel free to contact our U.S. based support team via email at contact@marketbeat.com.
If you no longer wish to receive email from DividendStocks.com, you can unsubscribe.
© 2006-2024 MarketBeat Media, LLC.
345 N Reid Place, Suite 620, Sioux Falls, SD 57103. United States.
|
|
|
|
